Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis

Relative overexpression of membrane-bound versus soluble TNF in spondyloarthritis

Bibliographic Details
Main Authors:	Ambarus Carmen A, van Duivenvoorde Leonie M, Masdar Huriatul, van Tok Melissa N, Tak Paul-Peter, Yeremenko Nataliya G, Baeten Dominique L
Format:	Article
Language:	English
Published:	BMC 2012-11-01
Series:	Journal of Translational Medicine

Similar Items

PENCEGAHAN KOMPLIKASI TUBERCULOSIS AKIBAT PEMBERIAN TNF-α ANTAGONIS
by: Huriatul Masdar
Published: (2009-05-01)

Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats
by: Melissa N. van Tok, et al.
Published: (2021-09-01)

Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats
by: Melissa N. van Tok, et al.
Published: (2017-08-01)

Identification of robust and disease-specific stromal alterations in spondyloarthritis synovitis
by: Yeremenko Nataliya, et al.
Published: (2011-11-01)

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling
by: Melissa N. van Tok, et al.
Published: (2018-07-01)

mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo
by: Sijia Chen, et al.
Published: (2020-02-01)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
by: Noordenbos Troy, et al.
Published: (2011-11-01)

Serum biomarkers to predict clinical response in proof-of-concept trials in spondyloarthritis
by: Turina Maureen, et al.
Published: (2011-11-01)

IL-17A producing mast cells as therapeutic target in spondyloarthritis
by: Canete J, et al.
Published: (2010-11-01)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
by: Jacqueline E. Paramarta, et al.
Published: (2016-10-01)

Insulin-Like Growth Factor I Does Not Drive New Bone Formation in Experimental Arthritis.
by: Melissa N van Tok, et al.
Published: (2016-01-01)

Data showing non-conventional HLA-B27 expression in axial joints and gut tissue from B27 transgenic rats, and in frozen and paraffin-fixed synovial SpA tissue
by: Oliwia Rysnik, et al.
Published: (2016-12-01)

APRIL Induces a Novel Subset of IgA+ Regulatory B Cells That Suppress Inflammation via Expression of IL-10 and PD-L1
by: Cynthia M. Fehres, et al.
Published: (2019-06-01)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
by: Jordi Gratacós, et al.
Published: (2019-01-01)

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs
by: Shirley Chiu Wai Chan, et al.
Published: (2021-07-01)

IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis
by: Atul Deodhar, et al.
Published: (2015-07-01)

The role of Bob1 in rheumatoid arthritis: potential implications for autoimmunity
by: Yeremenko Nataliya, et al.
Published: (2012-11-01)

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort
by: Janneke J. de Winter, et al.
Published: (2018-03-01)

Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis
by: I. Olivieri, et al.
Published: (2013-03-01)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
by: Agata Sebastian, et al.
Published: (2017-08-01)

TNF and IL-6 differentially regulate the production of DKK-1, a master regulator of bone remodelling, by fibroblast-like synoviocytes
by: Baeten D, et al.
Published: (2010-11-01)

TNF-related apoptosis-inducing ligand levels in rheumatoid arthritis, osteoarthritis, and spondyloarthritis
by: Mustafa Abdelaziz Mustafa, et al.
Published: (2012-01-01)

Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.
by: Ada Aita, et al.
Published: (2018-01-01)

Tie2 signaling cooperates with TNF to promote the pro-inflammatory activation of human macrophages independently of macrophage functional phenotype.
by: Samuel García, et al.
Published: (2014-01-01)

Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10.
by: Carmen A Ambarus, et al.
Published: (2012-01-01)

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system
by: Elsa How Shing Koy, et al.
Published: (2021-07-01)

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
by: Santiago Rodrigues Manica, et al.
Published: (2020-08-01)

ASSESSING ANTI-TNF TROUGH LEVELS AND ITS APPLICABILITY IN DAILY PRACTICE IN SPONDYLOARTHRITIS PATIENTS
by: Claudia Deaconu, et al.
Published: (2016-09-01)

Pelvic girdle enthesitis in spondyloarthritis
by: C Van Langenhove, et al.
Published: (2013-05-01)

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses
by: Silvia Menegatti, et al.
Published: (2019-03-01)

A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis ‘CRP-negative’
by: Robert Landewé, et al.
Published: (2018-09-01)

Soluble transferrin receptors and ferritin index in the diagnosis of iron deficiency in patients with spondyloarthritis and anemia
by: Karina N. Safarova, et al.
Published: (2021-05-01)

Ectopic bone formation and systemic bone loss in a transmembrane TNF-driven model of human spondyloarthritis
by: Eleni Christodoulou-Vafeiadou, et al.
Published: (2020-10-01)

Electrocardiographic changes in spondyloarthritis and use of anti-TNF-α drugs: a retrospective study with 100 patients
by: Betânia Longo, et al.

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
by: Borja Hernández-Breijo, et al.
Published: (2019-02-01)

Spondylodiscitis (Andersson lesion) in psoriatic spondyloarthritis: a rare event successfully treated with an anti-TNF therapy.
by: Vincenzo Bruzzese, et al.
Published: (2016-04-01)

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates
by: Stephanie Harvard, et al.
Published: (2017-09-01)

Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients
by: Inesa Arstikyte, et al.
Published: (2015-01-01)

Anti-TNF therapy in axial spondyloarthritis : mechanism of action and prediction of therapeutic responses using immunological signatures
by: Menegatti, Silvia
Published: (2017)

Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules.
by: Maria L Olleros, et al.
Published: (2012-01-01)

Cannot write session to /tmp/vufind_sessions/sess_i9i4u209h23mb3bivic85k7ceu